1. Home
  2. AHT vs APVO Comparison

AHT vs APVO Comparison

Compare AHT & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AHT

Ashford Hospitality Trust Inc

HOLD

Current Price

$4.33

Market Cap

26.2M

Sector

Real Estate

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$0.58

Market Cap

21.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHT
APVO
Founded
2003
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.2M
21.7M
IPO Year
2003
N/A

Fundamental Metrics

Financial Performance
Metric
AHT
APVO
Price
$4.33
$0.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
454.2K
1.8M
Earning Date
11-04-2025
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,119,102,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.90
$0.50
52 Week High
$10.35
$109.80

Technical Indicators

Market Signals
Indicator
AHT
APVO
Relative Strength Index (RSI) 58.85 21.42
Support Level $3.62 $0.50
Resistance Level $3.97 $1.11
Average True Range (ATR) 0.42 0.10
MACD 0.08 -0.05
Stochastic Oscillator 73.56 8.95

Price Performance

Historical Comparison
AHT
APVO

About AHT Ashford Hospitality Trust Inc

Ashford Hospitality Trust Inc. is a real estate investment trust that invests in full-service upscale and upper-upscale hotel properties in the U.S. The company owns and operates its assets through its operating partnership, Ashford Hospitality Limited Partnership. All of its hotels are located across the U.S. and operate under the Marriott, Hilton, Hyatt, Crowne Plaza, and Sheraton brands. Ashford's sole segment is Direct Hotel Investments, through which it owns hotels by acquisition or development. Ashford also provides real estate investment services, such as mezzanine financing, first mortgage financing, and sales-leaseback transactions. Its revenue streams include Room revenue, Food and beverage revenue, and Other revenue. Room revenue accounts for the majority of total revenue.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: